CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study
Authors
R. Carson
A. Chari
+19 more
M. Delioukina
C. Hulin
V. Hungria
S. Iida
L. Karlin
M. Kosh
H. Magen
V. Maisnar
T. Masterson
Helen McCarthy
D.A. Parasrampuria
A. Perrot
L. Pour
M. Qin
P. Rodriguez-Otero
A. Sureda Balari
K. Suzuki
C. Touzeau
S. Yang
Publication date
15 February 2021
Publisher
'Wiley'
Doi
Cite
Abstract
© 2020 The Authors. Daratumumab is a CD38-targeting monoclonal antibody approved for intravenous (IV) infusion for multiple myeloma (MM). We describe the Phase II PLEIADES study of a subcutaneous formulation of daratumumab (DARA SC) in combination with standard-of-care regimens: DARA SC plus bortezomib/lenalidomide/dexamethasone (D-VRd) for transplant-eligible newly diagnosed MM (NDMM); DARA SC plus bortezomib/melphalan/prednisone (D-VMP) for transplant-ineligible NDMM; and DARA SC plus lenalidomide/dexamethasone (D-Rd) for relapsed/refractory MM. In total, 199 patients were treated (D-VRd, n = 67; D-VMP, n = 67; D-Rd, n = 65). The primary endpoints were met for all cohorts: the ≥very good partial response (VGPR) rate after four 21-day induction cycles for D-VRd was 71·6% [90% confidence interval (CI) 61·2–80·6%], and the overall response rates (ORRs) for D-VMP and D-Rd were 88·1% (90% CI 79·5–93·9%) and 90·8% (90% CI 82·6–95·9%). With longer median follow-up for D-VMP and D-Rd (14·3 and 14·7 months respectively), responses deepened (ORR: 89·6%, 93·8%; ≥VGPR: 77·6%, 78·5%), and minimal residual disease–negativity (10‒5) rates were 16·4% and 15·4%. Infusion-related reactions across all cohorts were infrequent (≤9·0%) and mild. The median DARA SC administration time was 5 min. DARA SC with standard-of-care regimens demonstrated comparable clinical activity to DARA IV–containing regimens, with low infusion-related reaction rates and reduced administration time
Similar works
Full text
Open in the Core reader
Download PDF
Available Versions
Crossref
See this paper in CORE
Go to the repository landing page
Download from data provider
Last time updated on 20/04/2021
Bournemouth University Research Online
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:eprints.bournemouth.ac.uk:...
Last time updated on 25/11/2020
Diposit Digital de la Universitat de Barcelona
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:diposit.ub.edu:2445/174026
Last time updated on 03/03/2021